Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

2.4K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
2.4K
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

1.4K
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
1.4K
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

767
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
767
Genetic Lingo01:11

Genetic Lingo

118.5K
Overview
118.5K
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

2.0K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
2.0K
Lysosomal Hydrolases01:22

Lysosomal Hydrolases

4.8K
Lysosomes are the site for the degradation of macromolecules and biological polymers released during membrane trafficking events such as secretory, endocytic, autophagic, and phagocytic pathways. The membrane-enclosed area of the lysosome, called the lumen, contains hydrolytic enzymes active in an acidic environment. These acid hydrolases are functional at a pH between 4.5 and 5 and are involved in cellular processes such as cell signaling, energy metabolism, restoration of the plasma membrane,...
4.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Reply-letter to the editor-nutritional situation of enterally fed patients in neurological early rehabilitation and impact of nutritional status on functional outcome.

Clinical nutrition (Edinburgh, Scotland)·2019
Same author

Standardized nutritional supply versus individual nutritional assessment: Impact on weight changes, complications and functional outcome from neurological early rehabilitation.

Clinical nutrition (Edinburgh, Scotland)·2019
Same author

Nutritional situation of enterally fed patients in neurological early rehabilitation and impact of nutritional status on functional outcome.

Clinical nutrition (Edinburgh, Scotland)·2019
Same author

[Telerehabilitation can not replace traditional neurological rehabilitation].

Der Nervenarzt·2017
Same author

[Prolonged weaning during early neurological and neurosurgical rehabilitation : S2k guideline published by the Weaning Committee of the German Neurorehabilitation Society (DGNR)].

Der Nervenarzt·2017
Same author

[5-Year-Follow-up of the MEmbeR Multicenter Study on Medical-Occupational Rehabilitation].

Die Rehabilitation·2017
Same journal

[Digital health applications and adherence in depression: a qualitative study from the perspective of healthcare providers].

Der Nervenarzt·2026
Same journal

Der Nervenarzt·2026
Same journal

[Rare genetic diseases with frequent mental symptoms].

Der Nervenarzt·2026
Same journal

Der Nervenarzt·2026
Same journal

Der Nervenarzt·2026
Same journal

[From feeblemindedness to intellectual deficiency : Some comments from the forensic-psychiatric perspective on the replacement of the juridical term in the German Criminal Code (the criminal liability paragraph 20 StGB)].

Der Nervenarzt·2026
See all related articles

Related Experiment Video

Updated: Apr 13, 2026

Fractionation for Resolution of Soluble and Insoluble Huntingtin Species
07:08

Fractionation for Resolution of Soluble and Insoluble Huntingtin Species

Published on: February 27, 2018

10.2K

[Huntington's disease].

J D Rollnik1

  • 1Institut für neurorehabilitative Forschung (InFo) der BDH-Klinik Hessisch Oldendorf gGmbH, Assoziiertes Institut der Medizinischen Hochschule Hannover (MHH), Greitstr. 18-28, 31840, Hessisch Oldendorf, Deutschland, prof.rollnik@bdh-klinik-hessisch-oldendorf.de.

Der Nervenarzt
|May 6, 2015
PubMed
Summary
This summary is machine-generated.

Huntington's disease (HD) is a progressive neurodegenerative disorder. While no cure exists, gene silencing offers a promising avenue for future Huntington's disease therapies.

More Related Videos

Efficient and Scalable Production of Full-length Human Huntingtin Variants in Mammalian Cells using a Transient Expression System
10:52

Efficient and Scalable Production of Full-length Human Huntingtin Variants in Mammalian Cells using a Transient Expression System

Published on: December 10, 2021

3.1K
Whole-brain Segmentation and Change-point Analysis of Anatomical Brain MRI—Application in Premanifest Huntington's Disease
09:06

Whole-brain Segmentation and Change-point Analysis of Anatomical Brain MRI—Application in Premanifest Huntington's Disease

Published on: June 9, 2018

12.8K

Related Experiment Videos

Last Updated: Apr 13, 2026

Fractionation for Resolution of Soluble and Insoluble Huntingtin Species
07:08

Fractionation for Resolution of Soluble and Insoluble Huntingtin Species

Published on: February 27, 2018

10.2K
Efficient and Scalable Production of Full-length Human Huntingtin Variants in Mammalian Cells using a Transient Expression System
10:52

Efficient and Scalable Production of Full-length Human Huntingtin Variants in Mammalian Cells using a Transient Expression System

Published on: December 10, 2021

3.1K
Whole-brain Segmentation and Change-point Analysis of Anatomical Brain MRI—Application in Premanifest Huntington's Disease
09:06

Whole-brain Segmentation and Change-point Analysis of Anatomical Brain MRI—Application in Premanifest Huntington's Disease

Published on: June 9, 2018

12.8K

Area of Science:

  • Neurology
  • Genetics
  • Neurodegeneration

Context:

  • Huntington's disease (HD) affects approximately 8000 individuals in Germany.
  • HD is a progressive neurodegenerative disorder with hyperkinetic, psychiatric, and cognitive symptoms.

Purpose:

  • Review the clinical course, epidemiology, genetics, pathophysiology, and treatment of HD.
  • Analyze current and potential therapeutic strategies for HD.

Summary:

  • Diagnostic certainty for HD is achieved through genetic testing, with CAG repeat length impacting disease progression.
  • The precise mechanism of mutant huntingtin protein (mHTT) toxicity in HD is complex, leading to neuronal cell death.
  • Clinical trials have investigated various agents, including antioxidants and receptor modulators, with limited success.

Impact:

  • Currently, no disease-modifying therapies exist for Huntington's disease.
  • Gene silencing techniques, such as RNA interference, represent a promising future direction for effective HD treatment.